Targeting LY6E Inhibits Neuroblastoma Progression and Suppresses M2 Macrophage Polarization
Human Mutation · 2026-01 · 2026 (1)
DOI: 10.1155/humu/3003097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, online erschienen am 15.04.2026. Verfasst von Lijuan Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Health Management Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Re…. Hauptthemen laut MEDLINE: Neuroblastoma, Tumor-Associated Macrophages, Macrophages, Antigens, Ly. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Neuroblastoma is a pediatric malignancy characterized by significant clinical heterogeneity. Although MYCN amplification is a well‐established marker of high‐risk disease, its interplay with the tumor immune microenvironment—particularly tumor‐associated macrophages (TAMs)—remains poorly understood. In this study, we developed an integrated gene signature incorporating genes associated with both MYCN amplification status and TAM infiltration, leading to the identification of 16 differentially expressed genes implicated in both biological processes. Six of these genes (CMBL, LY6E, KLRB1, CTSH, CD3D, and PTGDS) were utilized to construct a risk‐scoring model that effectively stratified neuroblastoma patients into high‐ and low‐risk groups with significantly distinct clinical outcomes ( p < 0.001). Notably, LY6E emerged as the most prognostically significant gene within the signature. More importantly, we revealed that LY6E modulates M2‐type macrophage polarization in neuroblastoma for the first time, suggesting a novel mechanism through which it may contribute to shaping an immunosuppressive tumor microenvironment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Health Management Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Ther…
- Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biot…
- Department of Thyroid and Breast Surgery, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital) of Guangzhou Medical University, Qingyuan, Guangdong, China.
- The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Preven…
- Department of Phase I clinical trial, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevent…
Zitieren
APA
Li, L., Zeng, Y., Zhang, Q., Zhuang, G., Liu, Y., Wang, X., & Wang, Y. (2026). Targeting LY6E Inhibits Neuroblastoma Progression and Suppresses M2 Macrophage Polarization. Human Mutation, 2026(1). https://doi.org/10.1155/humu/3003097
Vancouver
Li L, Zeng Y, Zhang Q, Zhuang G, Liu Y, Wang X, et al. Targeting LY6E Inhibits Neuroblastoma Progression and Suppresses M2 Macrophage Polarization. Human Mutation. 2026;2026(1). doi:10.1155/humu/3003097
BibTeX
@article{Li2026,
author = {Li, Lijuan and Zeng, Yu and Zhang, Qinfen and Zhuang, Gaojian and Liu, Yu and Wang, Xuan and Wang, Yuqi},
title = {Targeting LY6E Inhibits Neuroblastoma Progression and Suppresses M2 Macrophage Polarization},
journal = {Human Mutation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/humu/3003097}
}
EUVIMED